Design, Synthesis, and In Vitro Activity of Pyrazine Compounds

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Cancer cells evade therapies through complex intracellular signaling pathways.
• Protein tyrosine phosphatases (PTPs), particularly SHP2, play a crucial role in regulating cell proliferation, migration, and metabolism, making them key targets in cancer research.
• Existing anticancer drugs face challenges due to cancer's adaptive evolution.

Purpose of the Study:

• To design and synthesize novel pyrazine-based small molecules as potential anticancer agents.
• To optimize the known inhibitor SHP099 using structure-based drug design.
• To identify new inhibitors targeting the SHP2 protein pathway.

Main Methods:

• Structure-based drug design was employed to optimize the SHP099 inhibitor.
• A 1-(methylsulfonyl)-4-prolylpiperazine linker was introduced.
• Three pyrazine-based small molecules were synthesized, utilizing prolines as cyclic amines.
• New hydrogen bond interactions were identified and confirmed.

Main Results:

• Three novel pyrazine-based small molecules were successfully designed and synthesized.
• The synthesized compounds maintained key interactions with the target protein, consistent with existing literature.
• A novel hydrogen bond interaction was identified in the optimized structures.
• Methyl (6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl)prolylprolinate hydrochloride was identified as a potent cytotoxic agent.

Conclusions:

• The developed pyrazine-based compounds, particularly methyl (6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl)prolylprolinate hydrochloride, demonstrate significant potential as anticancer agents.
• Structure-based drug design and optimization of known inhibitors like SHP099 can lead to the discovery of effective cytotoxic compounds.
• Targeting the SHP2 protein pathway with novel small molecules offers a promising strategy for cancer therapy.